GENOVAX S.R.L.
The story goes that during a smallpox epidemic in 1718, Lady Wortley Montague, wife of the British ambassador to the Turkish sultan in Istanbul, noted how the Turks breathed smallpox crusts into the nose of healthy people who did not contract the disease .
GENOVAX S.R.L.
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Address:
Turin, Piemonte, Italy
Country:
Italy
Website Url:
http://www.genovax.it
Status:
Active
Contact:
+39 0125 561000
Email Addresses:
[email protected]
Technology used in webpage:
SPF SSL By Default LetsEncrypt Apache PHP Register.IT DNS
Similar Organizations
ActoBio Therapeutics
ActoBio Therapeutics develops therapeutic agents that treat a number of diseases, primarily on disease areas with high unmet needs.
Current Employees Featured
Official Site Inspections
http://www.genovax.it
- Host name: lhcp3405.webapps.net
- IP address: 81.88.53.155
- Location: Italy
- Latitude: 43.1479
- Longitude: 12.1097
- Timezone: Europe/Rome
More informations about "Genovax s.r.l."
Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin)
Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) General Information Description. GX301 is a clinical-stage therapeutic vaccine based in Torino, Italy. The vaccine is composed …See details»
Genovax s.r.l. - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +39 0125 561000 The story goes that during a smallpox epidemic in 1718, Lady Wortley Montague, wife of the British ambassador to the …See details»
Genovax Company Profile 2024: Valuation, Funding
Genovax General Information Description. Developer of therapeutic drugs designed to explore the potential of vaccination in various chronic pathologies. The company's drugs are used for the treatment of systemic lupus …See details»
Genovax - Products, Competitors, Financials, Employees, …
Genovax is a company involved in vaccine development in the biotechnology industry. It conducts research and creation of vaccines intended to prevent infectious diseases by administering …See details»
Eporgen's Portfolio Company Genovax Sells GX301, its Clinical …
Dec 3, 2012 Genovax srl is a privately held company based in Colleretto Giacosa (Torino, Italy) and is focusing on the development of therapeutic vaccines against cancer, such as GX301, or …See details»
Genovax s.r.l. - BioCentury Company Profiles - BCIQ
May 13, 2013 Genovax s.r.l. - BioCentury Company Profiles for the biopharma industrySee details»
Genovax S.r.l. - LinkedIn
Chemsafe Srl Business Consulting and Services Parella, Piemonte exida Engineering Services Sellersville, PASee details»
Eporgen's Portfolio Company Genovax Sells GX301, its Clinical …
Dec 3, 2012 The acquisition of Genovax's innovative therapeutic vaccine for the treatment of various type of cancer is part of a strategy that we initiated since the late '90s and is a …See details»
Mediolanum Acquires Phase II-Ready Cancer Vaccine From Italy’s …
Dec 4, 2012 Italian life sciences seed capital firm Eporgen Venture has used a network of wealthy individuals in Italy to fund a group of new biotech companies, and has entered into its …See details»
Italy's Genovax Sells Therapeutic Cancer Vaccine Rights to …
Dec 4, 2012 Skip to Main Content. PRODUCTS. WSJ.comSee details»
Research programme: systemic lupus erythematosus gene therapy …
Jul 16, 2016 Genovax is developing GX 101, a tolerogenic gene therapy for systemic lupus erythematosus, which consists of a Consensus peptide-Fc immunoglobulin chimera. The ... If …See details»
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is …
Apr 17, 2013 Background Anti-tumor vaccination is a new frontier in cancer treatment applicable to immunogenic neoplasms such as prostate and renal cancers. GX301 is a vaccine …See details»
A Newcastle disease virus expressing a stabilized spike ... - Nature
Oct 27, 2021 A survey conducted by The World Health Organization (WHO) estimated the production capacity for pandemic influenza vaccines (monovalent) could reach ~4.15 billion …See details»
Safety and immunogenicity of an inactivated recombinant …
Oct 13, 2021 PN, SSur, SPra, SPuk, RK, RSin, NS, SThe, TV, KP, and PW are salaried employees of the Government Pharmaceutical Organization (Thailand). RH is a paid …See details»
Systemic Measures and Legislative and Organizational …
Jan 18, 2018 More detailed characteristics of drug shortages, analyses of information systems and their role in coping with shortages, detailed descriptions of initiatives, and organizational …See details»
Genevax Company Profile 2024: Valuation, Funding & Investors
Genevax General Information Description. Developer of innovative vaccines designated to meet public health challenges and health needs. The company's vaccines focuses on innovative …See details»
GX 301 - AdisInsight - Springer
GX 301 is a cancer vaccine being developed by Mediolanum Farmaceutici under a license from Genovax, for the treatment of prostate cancer. The vaccine has four GX 301 Next ... If your …See details»
GeoVax - Wikipedia
GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara (MVA) vector technology, with …See details»
Genoox Company Profile 2024: Valuation, Funding & Investors
Genoox General Information Description. Developer of genomic analytics designed to translate complex genetic data into useful clinical information. The company's platform uses artificial …See details»
GeoVax Labs, Inc. | LinkedIn
GeoVax Labs, Inc., (NASDAQ: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara - Virus-Like …See details»